tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Alterity Therapeutics Advances in Neurodegenerative Disease Treatment
Company AnnouncementsAlterity Therapeutics Advances in Neurodegenerative Disease Treatment
2d ago
Alterity Therapeutics CEO Outlines Strategic Vision
PremiumCompany Announcements
Alterity Therapeutics CEO Outlines Strategic Vision
2d ago
Alterity Therapeutics Advances in Neurodegenerative Disease Treatment
PremiumCompany Announcements
Alterity Therapeutics Advances in Neurodegenerative Disease Treatment
2d ago
Alterity Therapeutics Announces Board Restructuring for Growth
PremiumCompany Announcements
Alterity Therapeutics Announces Board Restructuring for Growth
2d ago
Alterity ‘never lost sight’ of interest in Parkinson’s disease, CEO says
PremiumThe Fly
Alterity ‘never lost sight’ of interest in Parkinson’s disease, CEO says
3d ago
ATHE
Alterity CEO says to meet with FDA, move forward with Phase 3 study
PremiumThe FlyAlterity CEO says to meet with FDA, move forward with Phase 3 study
3d ago
ATHE
Alterity ‘really emerging’ as U.S. company, CEO tells The Fly
Premium
The Fly
Alterity ‘really emerging’ as U.S. company, CEO tells The Fly
3d ago
ATHE
Stamler says Alterity treating neurodegeneration in ‘way no one else is doing’
Premium
The Fly
Stamler says Alterity treating neurodegeneration in ‘way no one else is doing’
3d ago
ATHE
Meet Alterity Therapeutics: Fly exclusive interview with CEO David Stamler
PremiumThe Fly
Meet Alterity Therapeutics: Fly exclusive interview with CEO David Stamler
3d ago
ATHE
Alterity Therapeutics Discloses Equity Derivative Positions
PremiumCompany Announcements
Alterity Therapeutics Discloses Equity Derivative Positions
10d ago
Alterity Therapeutics to Present Key Updates at Bell Potter Healthcare Conference
PremiumCompany Announcements
Alterity Therapeutics to Present Key Updates at Bell Potter Healthcare Conference
11d ago
Alterity Therapeutics presents analyses related to OH from ATH434-201 trial
PremiumThe Fly
Alterity Therapeutics presents analyses related to OH from ATH434-201 trial
13d ago
ATHE
Alterity Therapeutics Reports Promising ATH434 Results in MSA Treatment
PremiumCompany AnnouncementsAlterity Therapeutics Reports Promising ATH434 Results in MSA Treatment
13d ago
Alterity Therapeutics reports cash balance of A$54.46M as of September 30
Premium
The Fly
Alterity Therapeutics reports cash balance of A$54.46M as of September 30
23d ago
ATHE
Alterity Therapeutics Advances MSA Treatment with Promising ATH434 Trial Results
Premium
Company Announcements
Alterity Therapeutics Advances MSA Treatment with Promising ATH434 Trial Results
23d ago
Alterity Therapeutics Announces 2025 Annual General Meeting
PremiumCompany Announcements
Alterity Therapeutics Announces 2025 Annual General Meeting
1M ago
Promising Phase 2 Results for ATH434 Boost Alterity Therapeutics’ Buy Rating
PremiumRatings
Promising Phase 2 Results for ATH434 Boost Alterity Therapeutics’ Buy Rating
1M ago
ATHE
Alterity Therapeutics presents data from ATH434 Phase 2 trial
PremiumThe Fly
Alterity Therapeutics presents data from ATH434 Phase 2 trial
1M ago
ATHE
Alterity Therapeutics to Present Promising Phase 2 Trial Results for MSA Treatment at 2025 Congress
PremiumCompany Announcements
Alterity Therapeutics to Present Promising Phase 2 Trial Results for MSA Treatment at 2025 Congress
2M ago
Alterity Therapeutics Projects $2.4 Billion Sales for MSA Drug ATH434
PremiumCompany AnnouncementsAlterity Therapeutics Projects $2.4 Billion Sales for MSA Drug ATH434
2M ago
Alterity Therapeutics Announces Director’s Interest Change
Premium
Company Announcements
Alterity Therapeutics Announces Director’s Interest Change
2M ago
Alterity Therapeutics Announces Cessation of 35 Million Securities
Premium
Company Announcements
Alterity Therapeutics Announces Cessation of 35 Million Securities
2M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >